echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > 2 over 2 billion varieties of Sialon Pharmaceuticals were reviewed on the same day

    2 over 2 billion varieties of Sialon Pharmaceuticals were reviewed on the same day

    • Last Update: 2022-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      A few days ago, Sialon Pharmaceutical announced that the company's wholly-owned subsidiary Hunan Sailon Pharmaceutical's tigecycline for injection and thymosin for injection passed the consistency evaluation
    .
    According to data from Minet.
    com, the sales volume of these two injections in public medical institutions in China will exceed 2 billion yuan in 2020

    .
     
      Tigecycline, a glycylcycline anti-infective drug, is clinically used for complex intra-abdominal infections, complex skin and skin and soft tissue infections, and community-acquired bacterial pneumonia caused by sensitive strains of specific bacteria
    .
     
      There are 11 domestic pharmaceutical companies that have approval for the production of tigecycline for injection.
    According to Minet.
    com, the product will be used in urban public
    hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2020.
    Terminal sales are close to 2.
    5 billion yuan, a year-on-year increase of 6.
    42% in the first half of 2021

    .
    Judging from the competition pattern of manufacturers, Hansoh, Pfizer and Chia Tai Tianqing rank among the top three

    .
     
      Application of Consistency Evaluation of Tigecycline for Injection
      Source: Minet Consistency Evaluation Database
     
      Tigecycline for injection is planned to be included in the seventh batch of centralized procurement.
    At present, including Sialon Pharmaceuticals, the products of 9
    companies have passed or are deemed to have passed the consistency evaluation and obtained admission tickets for centralized procurement
    .
     
      According to the data from Minet.
    com, there are currently 8 varieties of Sialon Pharmaceuticals that have passed or are deemed to have passed the consistency evaluation, all of which are injections, of which 3 are digestive system and metabolic drugs

    .
     
      Sialon Pharmaceutical's over-evaluation
      Source: MED2.
    0 China Drug Evaluation Database
     
      In addition to tigecycline for injection, milrinone injection and omeprazole sodium for injection are also planned to be included in the seventh batch of centralized procurement.
    The three injections are all the best-selling drugs in the terminals of public medical institutions in China.
    market share is low

    .
     
      Source: Mi Intranet database, announcements of listed companies, etc.
      A few days ago, Sialon Pharmaceutical announced that the company's wholly-owned subsidiary Hunan Sailon Pharmaceutical's tigecycline for injection and thymosin for injection passed the consistency evaluation
    .
    According to data from Minet.
    com, the sales volume of these two injections in public medical institutions in China will exceed 2 billion yuan in 2020

    .
     
      Tigecycline, a glycylcycline anti-infective drug, is clinically used for complex intra-abdominal infections, complex skin and skin and soft tissue infections, and community-acquired bacterial pneumonia caused by sensitive strains of specific bacteria
    .
     
      There are 11 domestic pharmaceutical companies that have approval for the production of tigecycline for injection.
    According to Minet.
    com, the product will be used in urban public
    hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2020.
    Terminal sales are close to 2.
    5 billion yuan, a year-on-year increase of 6.
    42% in the first half of 2021

    .
    Judging from the competition pattern of manufacturers, Hansoh, Pfizer and Chia Tai Tianqing rank among the top three

    .
     
      Application of Consistency Evaluation of Tigecycline for Injection
      Source: Minet Consistency Evaluation Database
     
      Tigecycline for injection is planned to be included in the seventh batch of centralized procurement.
    At present, including Sialon Pharmaceuticals, the products of 9
    companies have passed or are deemed to have passed the consistency evaluation and obtained admission tickets for centralized procurement
    .
     
      According to the data from Minet.
    com, there are currently 8 varieties of Sialon Pharmaceuticals that have passed or are deemed to have passed the consistency evaluation, all of which are injections, of which 3 are digestive system and metabolic drugs

    .
     
      Sialon Pharmaceutical's over-evaluation
      Source: MED2.
    0 China Drug Evaluation Database
     
      In addition to tigecycline for injection, milrinone injection and omeprazole sodium for injection are also planned to be included in the seventh batch of centralized procurement.
    The three injections are all the best-selling drugs in the terminals of public medical institutions in China.
    market share is low

    .
     
      Source: Mi Intranet database, announcements of listed companies, etc.
      A few days ago, Sialon Pharmaceutical announced that the company's wholly-owned subsidiary Hunan Sailon Pharmaceutical's tigecycline for injection and thymosin for injection passed the consistency evaluation
    .
    According to data from Minet.
    com, the sales volume of these two injections in public medical institutions in China will exceed 2 billion yuan in 2020

    .
     
      Tigecycline, a glycylcycline anti-infective drug, is clinically used for complex intra-abdominal infections, complex skin and skin and soft tissue infections, and community-acquired bacterial pneumonia caused by sensitive strains of specific bacteria
    .
     
      There are 11 domestic pharmaceutical companies that have approval for the production of tigecycline for injection.
    According to Minet.
    com, the product will be used in urban public
    hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2020.
    Terminal sales are close to 2.
    5 billion yuan, a year-on-year increase of 6.
    42% in the first half of 2021

    .
    Judging from the competition pattern of manufacturers, Hansoh, Pfizer and Chia Tai Tianqing rank among the top three

    .
    hospital hospital hospital
     
      Application of Consistency Evaluation of Tigecycline for Injection
      Source: Minet Consistency Evaluation Database
     
      Tigecycline for injection is planned to be included in the seventh batch of centralized procurement.
    At present, including Sialon Pharmaceuticals, the products of 9
    companies have passed or are deemed to have passed the consistency evaluation and obtained admission tickets for centralized procurement
    .
    enterprise enterprise enterprise
     
      According to the data from Minet.
    com, there are currently 8 varieties of Sialon Pharmaceuticals that have passed or are deemed to have passed the consistency evaluation, all of which are injections, of which 3 are digestive system and metabolic drugs

    .
     
      Sialon Pharmaceutical's over-evaluation
      
      Source: MED2.
    0 China Drug Evaluation Database
     
      In addition to tigecycline for injection, milrinone injection and omeprazole sodium for injection are also planned to be included in the seventh batch of centralized procurement.
    The three injections are all the best-selling drugs in the terminals of public medical institutions in China.
    market share is low

    .
     
      Source: Mi Intranet database, announcements of listed companies, etc.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.